knowledge -WSS

knowledge

author：Wikipedia 2025-09-29 00:40:44 - browse：454

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Some top drug companies are starting to take action on climate

hotspot

WSS

FDA gives detailed accounting of AI

The United States is paying nearly triple for new Covid vaccines

Flu, Covid vaccination rates decline, new survey data show

CDC picks Alphabet's Verily for wasterwater surveillance contract

Nobel honors Karikó and Weissman's enduring partnership

CRISPR base editing slashes cholesterol levels in monkeys

explore

knowledge

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Lawmakers consider Medicare pay reforms for doctors

How to save PrEP access — and even expand it

First Opinion Podcast: Long Covid needs a new approach

Hollywood unions extend contract negotiations for actors

UnitedHealth’s board chair also owns a personal investment firm

Malaria cases in Florida and Texas: Here’s what you need to know

CDC picks Alphabet's Verily for wasterwater surveillance contract

Hepatitis C has a cure — but many Americans still lack access to it

The explosion of genetic testing requires a new approach

focus

STAT Summit: GSK CEO on pharma giant's new direction

Stop Congress from blocking public access to science

Lawsuit highlights wrinkle for disputes over surprise medical bills

The EU Joint Clinical Assessment needs to live up to its promise

How climate

Nobel honors Karikó and Weissman's enduring partnership

entertainment

hotspot

hotspot

focus